The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents

被引：7

作者：

Asshoff, Malte ^{[1
]}

Warr, Matthew ^{[2
]}

Haschka, David ^{[1
]}

Tymoszuk, Piotr ^{[1
]}

Petzer, Verena ^{[1
]}

Demetz, Egon ^{[1
]}

Maciejewski, Pat ^{[2
]}

Seifert, Markus ^{[1
]}

Nairz, Manfred ^{[1
]}

Posch, Wilfried ^{[3
]}

Fowles, Peter ^{[2
]}

Weiss, Guenter ^{[1
]}

Whitney, Andy ^{[2
]}

Theurl, Igor ^{[1
]}

机构：

[1] Med Univ Innsbruck, Internal Med 6, A-6020 Innsbruck, Austria

[2] Gilead Sci, Branford, CT USA

[3] Med Univ Innsbruck, Divsison Hyg & Med Microbiol, A-6020 Innsbruck, Austria

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.538.538

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Verstovsek, Srdan
Kantarjian, Hagop
Mesa, Ruben A.
Pardanani, Animesh D.
Cortes-Franco, Jorge
Thomas, Deborah A.
Estrov, Zeev
Fridman, Jordan S.
Bradley, Edward C.
Erickson-Viitanen, Susan
Vaddi, Kris
Levy, Richard
Tefferi, Ayalew
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127
[22] Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice
Trivedi, Prerak M.
Graham, Kate L.
Scott, Nicholas A.
Jenkins, Misty R.
Majaw, Suktilang
Sutherland, Robyn M.
Fynch, Stacey
Lew, Andrew M.
Burns, Christopher J.
Krishnamurthy, Balasubramanian
Brodnicki, Thomas C.
Mannering, Stuart I.
Kay, Thomas W.
Thomas, Helen E.
DIABETES, 2017, 66 (06) : 1650 - 1660
[23] Discovery of CYT387: A potent and selective dual inhibitor of JAK1 and JAK2
Burns, Christopher J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[24] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
Gisslinger, H.
Skrabs, C.
Gisslinger, B.
Schoder, R.
Muellauer, L.
Kralovics, R.
HAEMATOLOGICA, 2013, 98 : 346 - 347
[25] Differential NK-suppressive capacity of the JAK2 inhibitor Pacritinib when compared to the JAK1/2 inhibitor Ruxolitinib
Wolf, D.
Rudolph, J.
Brossart, P.
Schoenberg, K.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 26 - 26
[26] Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib
Wei, Qing
Xu, Jie
BLOOD, 2024, 144 (02) : 238 - 238
[27] BARICITINIB Tyrosine-Protein Kinase JAK1/JAK2 Inhibitor Treatment of Rheumatoid Arthritis
Gras, Jordi
DRUGS OF THE FUTURE, 2013, 38 (09) : 611 - 617
[28] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Jaekel, N.
Behre, G.
Behning, A.
Wickenhauser, C.
Lange, T.
Niederwieser, D.
Al-Ali, H. K.
BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
[29] The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
Aktimur, Sude H.
Malkan, Umit Y.
Eyupoglu, Damla N.
Haznedaroglu, Ibrahim C.
Kelkitli, Engin
Atay, Hilmi M.
Gunes, Gursel
Etgul, Sezgin
Aslan, Tuncay
Goker, Hakan
Sayinalp, Nilgun
Aksu, Salih
Ozcebe, Osman I.
Buyukasik, Yahya
Turgut, Mehmet
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (03): : 153 - 158
[30] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
N Jaekel
G Behre
A Behning
C Wickenhauser
T Lange
D Niederwieser
H K Al-Ali
Bone Marrow Transplantation, 2014, 49 : 179 - 184

← 1 2 3 4 5 →